Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...

Aortic valve stenosis” is an often-overlooked condition and a growing health concern in ageing societies such as Thailand.

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...